Pharma & Bio
Technology
ILDONG PHARM Signs Term Sheet with Global Pharmaceutical Company for Padoprazan... Will It Shake Up the P-CAB Three-Way Race?
ILDONG PHARM(249420)has proven the value of Padoprazan on the global stage and has entered a race to accelerate its commercialization. This comes as partnership discussions in the U.S. are in full swi…
Lifestyle
Rigacem, Chosen by the Government... The K-Bio Investment Formula That 500 Billion Won Will Change
The government has, for the first time, injected large-scale policy funds into late-stage clinical trials for new drug development. This comes as the National Growth Fund has decided to make a direct …
Lifestyle
[K-Bio Pulse] Black Friday Hits Korean Biotech
South Korea’s pharmaceutical and biotech sector suffered broad-based losses on July 3 in what resembled a “Black Friday” for the industry. Stocks that had recently announced major positive development…
Lifestyle
Both Good and Bad News Were Shaken Off… K-Bio Faces 'Black Friday' [Bio Spotlight]
On the 3rd, pharmaceutical and biotech stocks plummeted across the board, creating a day reminiscent of “Black Friday.” Stocks that had been riding a wave of positive news—including LigaChem Bioscienc…
Business·Industry
Shin Tae-hyun, CEO of Inventera Inc.: “With Infinity, We’re Moving Beyond Precision Diagnostics to Take on Drug Delivery Therapies”
“Inventera Inc. is a company specializing in nanopharmaceuticals that develops diagnostic tools and therapeutics based on platform technologies that overcome the limitations of immune cell phagocytosi…
Business·Industry
K-Bio Secures Solid Funding… What Do They Have in Common?
Large-scale domestic capital is flowing into proven platform-based biotech companies, evolving into long-term growth funding for global new drug development.
Status of Large-Scale Investment Attrac…
Technology
LigaChem Biosciences’ ‘Hidden Cash Cow’ for the Second Half… Expectations for Revenue from Technology Transfer
LigaChem Biosciences(141080)is poised to benefit from two key drivers in the second half of the year: cash inflows and the release of key clinical data. This is because, amid growing expectations rega…
Technology
[Space Bio: Part 2] K-Bio Chases Big Pharma… Aims for Sovereignty in Space-Based New Drugs
The reasons why Korea’s pharmaceutical and biotech industries are turning their attention to space lie in cost and sovereignty. In a microgravity environment, the costs and time required for new drug …
Technology
Curiox Expands Business from 'Equipment' to 'Software'... Contract with Big Pharma Serves as a Signal
Curiox Biosystems Co., Ltd.(445680)(Curiox) is set to improve its earnings structure by expanding its software (SW) business. Having remained at around 5 billion won in revenue for several years since…
Business·Industry
'From HLB INC.’s Day of Reckoning to TG-C’s Revenge Match'… July’s Hot Topics in K-Bio [Monthly Spotlight]
The major events in the biotech industry in July can be summarized as the decision on whether to grant marketing approval for HLB INC.(028300) ’s new liver cancer drug, Riboceranib, and the release of…